Clinical relevance of total choline (tCho) quantification in suspicious lesions on multiparametric breast MRI

[1]  김창호,et al.  35. , 1991, Maxime Planoudes, Lettres.

[2]  E. Morris,et al.  Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) , 2019, Breast Cancer Research and Treatment.

[3]  E. Morris,et al.  Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) , 2018, Breast Cancer Research and Treatment.

[4]  J. Allen,et al.  Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  T. Helbich,et al.  A survey by the European Society of Breast Imaging on the utilisation of breast MRI in clinical practice , 2017, European Radiology.

[6]  L. Tafra,et al.  Positive Ultrasound-guided Lymph Node Needle Biopsy in Breast Cancer may not Mandate Axillary Lymph Node Dissection , 2017, Annals of Surgical Oncology.

[7]  Maria Bernathova,et al.  A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions , 2017, European Radiology.

[8]  Wolfgang Bogner,et al.  Diffusion-weighted imaging of breast lesions: Region-of-interest placement and different ADC parameters influence apparent diffusion coefficient values , 2017, European Radiology.

[9]  R. Beets-Tan,et al.  Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients. , 2016, European journal of radiology.

[10]  E. Morris,et al.  First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) , 2016, Breast Cancer Research and Treatment.

[11]  P. Baltzer,et al.  Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis , 2016, PloS one.

[12]  M. Dietzel,et al.  Combined reading of Contrast Enhanced and Diffusion Weighted Magnetic Resonance Imaging by using a simple sum score , 2016, European Radiology.

[13]  Kristine Glunde,et al.  Choline metabolism-based molecular diagnosis of cancer: an update , 2015, Expert review of molecular diagnostics.

[14]  M. Dowsett,et al.  Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer , 2015, Breast Cancer Research.

[15]  M. Chung,et al.  Measuring the impact of the American College of Surgeons Oncology Group Z0011 trial on breast cancer surgery in a community health system. , 2015, American journal of surgery.

[16]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Ralf-Dieter Hilgers,et al.  Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Helbich,et al.  Improved Diagnostic Accuracy With Multiparametric Magnetic Resonance Imaging of the Breast Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and 3-Dimensional Proton Magnetic Resonance Spectroscopic Imaging , 2014, Investigative radiology.

[19]  T. Helbich,et al.  MRI-only lesions: application of diffusion-weighted imaging obviates unnecessary MR-guided breast biopsies , 2014, European Radiology.

[20]  F. Cardoso,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Beets-Tan,et al.  Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? , 2013, Breast.

[22]  Mi Young Kim,et al.  Mammographic and ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes , 2013, Acta radiologica.

[23]  C. A. Azlan,et al.  Improved diagnostic accuracy in differentiating malignant and benign lesions using single-voxel proton MRS of the breast at 3 T MRI. , 2013, Clinical radiology.

[24]  Matthias Dietzel,et al.  Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T--systematic review and meta-analysis. , 2013, Radiology.

[25]  W. Kaiser,et al.  A simple and robust classification tree for differentiation between benign and malignant lesions in MR-mammography , 2013, European Radiology.

[26]  K. Pinker,et al.  Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the “Breast Imaging Reporting and Data System” for multiparametric 3-T imaging of breast lesions , 2013, European Radiology.

[27]  W. Kaiser,et al.  Association between survival in patients with primary invasive breast cancer and computer aided MRI , 2013, Journal of magnetic resonance imaging : JMRI.

[28]  Lorenzo Bonomo,et al.  Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors. , 2012, Clinical breast cancer.

[29]  U. Sharma,et al.  Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: An MRI and in vivo proton MRS study , 2012, Magnetic resonance in medicine.

[30]  W. Kaiser,et al.  A simple and robust classification tree for differentiation between benign and malignant lesions in MR-mammography. , 2012, European journal of radiology.

[31]  H. Baek.  Diagnostic Value of Breast Proton Magnetic Resonance Spectroscopy at 1.5T in Different Histopathological Types , 2012, TheScientificWorldJournal.

[32]  Eun-Kyung Kim,et al.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes , 2012, European Radiology.

[33]  W. Kaiser,et al.  Effect of contrast agent on the results of in vivo 1H MRS of breast tumors – is it clinically significant? , 2012, NMR in biomedicine.

[34]  M. Oudkerk,et al.  The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging , 2011, European Radiology.

[35]  W. Kaiser,et al.  Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an extended protocol in an initial prospective study. , 2011, AJR. American journal of roentgenology.

[36]  Wei Huang,et al.  Diagnostic usefulness of water‐to‐fat ratio and choline concentration in malignant and benign breast lesions and normal breast parenchyma: An in vivo 1H MRS study , 2011, Journal of magnetic resonance imaging : JMRI.

[37]  W. Kaiser,et al.  Potential of MR mammography to predict tumor grading of invasive breast cancer. , 2011, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[38]  W. Kaiser,et al.  Application of artificial neural networks for the prediction of lymph node metastases to the ipsilateral axilla – initial experience in 194 patients using magnetic resonance mammography , 2010, Acta radiologica.

[39]  Roberto Orecchia,et al.  Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. , 2010, European journal of cancer.

[40]  Werner A. Kaiser,et al.  Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer , 2010, European Radiology.

[41]  Donald B. Plewes,et al.  Evaluation of multicoil breast arrays for parallel imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[42]  R. Lenkinski,et al.  Interaction of gadolinium‐based MR contrast agents with choline: Implications for MR spectroscopy (MRS) of the breast , 2009, Magnetic resonance in medicine.

[43]  Michael Garwood,et al.  Metabolite quantification and high‐field MRS in breast cancer , 2009, NMR in biomedicine.

[44]  Les Irwig,et al.  Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Boetes,et al.  Breast MRI: guidelines from the European Society of Breast Imaging , 2008, European Radiology.

[46]  F. Schmidt,et al.  Magnetic resonance imaging (MRI) of the breast , 1997, Acta Chirurgica Austriaca.

[47]  Hon J. Yu,et al.  Quantification of Choline-containing Compounds in Malignant Breast Tumors by 1H MR Spectroscopy Using Water as an Internal Reference at 1.5 T , 2006, Magnetic Resonance Materials in Physics, Biology and Medicine.

[48]  N R Jagannathan,et al.  Biochemical characterization of metastatic lymph nodes of breast cancer patients by in vitro 1H magnetic resonance spectroscopy: a pilot study. , 2004, Magnetic resonance imaging.

[49]  E. Grabbe,et al.  Classification of hypervascularized lesions in CE MR imaging of the breast , 2002, European Radiology.

[50]  Vanhamme,et al.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.